Aerococcus Urinae: Characteristics, Pathogenicity, and Antibiotic Resistance

Aerococcus urinae is a gram-positive bacterium that primarily causes urinary tract infections in older adults and, less commonly, serious invasive infections like endocarditis and spinal infections. Despite being recognized as a human pathogen for decades, it has historically been underdiagnosed because routine laboratory systems frequently mistake it for other bacteria. Newer identification technology is changing that picture, and the organism is showing up in clinical cultures far more often than it used to.

What Aerococcus Urinae Looks Like Under the Microscope

A. urinae is a gram-positive coccus, meaning it appears as round cells that retain a violet stain. It grows in pairs and clusters, produces alpha-hemolysis (a greenish discoloration) on blood agar plates, and tests negative for both catalase and a specific enzyme called pyrrolidonyl aminopeptidase.¹ That combination of features makes it easy to confuse with streptococci, enterococci, or staphylococci, especially because A. urinae has historically been absent from the databases of most commercial identification systems used in hospital labs.¹ Genomic studies show that A. urinae strains have relatively compact genomes, ranging from about 1.93 to 2.44 million base pairs, with substantial diversity among strains in terms of genome size and the genes they carry.²

Why Labs Have Missed It for So Long

For years, many clinical microbiology labs simply could not identify A. urinae reliably. The automated systems they used to classify bacteria did not include it in their reference databases, so cultures would come back labeled as an enterococcus or a viridans streptococcus. This meant that patients were sometimes prescribed antibiotics that targeted the wrong organism. The introduction of a newer technology called MALDI-TOF mass spectrometry changed things substantially. This method identifies bacteria by analyzing their protein signatures and matching them against a database, and it has proven both sensitive and specific for aerococci.³

The practical effect is striking. At one Australian hospital, the identification rate of Aerococcus in urine cultures more than doubled after MALDI-TOF was adopted, going from roughly 15 per 100,000 patients per year to 32 per 100,000.⁴ That jump almost certainly reflects better detection rather than a genuine increase in infections. In other words, A. urinae was always there; labs just were not finding it.

Who Gets Infected

A. urinae is overwhelmingly a pathogen of older people. In one epidemiological study, the median age of patients with aerococcal bacteriuria was 83 years, significantly higher than the median age for patients with E. coli or Enterococcus faecalis urinary infections.⁵ A separate case review put the typical patient’s median age at 79.⁶ Men and women appear to be affected in roughly equal proportions with aerococcal bacteriuria, which is unusual for urinary pathogens since E. coli UTIs, for example, are far more common in women.⁵ One chart review of 92 patients did find a female majority (76–87%) among both A. sanguinicola and A. urinae urine isolates, so this balance may depend on the population studied.⁷

The risk factors paint a clear picture: advanced age, multiple chronic conditions, and anything that interferes with normal urinary flow. Urinary retention, benign prostatic enlargement, prostate or bladder cancer, long-term catheter use, diabetes, heart disease, and chronic kidney disease have all been linked to higher susceptibility.⁸ In one retrospective review, a majority of male patients with either A. urinae or A. sanguinicola had underlying prostatic disease, and most patients overall were institutionalized.⁷ While the organism can occasionally appear in younger patients and even children, pediatric cases are rare and A. urinae is usually found alongside other bacteria rather than alone in those settings.⁹

How It Causes Disease

Most A. urinae infections start in the urinary tract. Symptoms resemble a standard UTI and can include painful urination, frequent urges, nighttime urination, blood in the urine, groin pain, fever, and confusion.⁶ The confusion is worth highlighting, because in elderly patients, altered mental status may be the most prominent sign, making it easy to overlook the urinary source.

At the molecular level, researchers have found that A. urinae strains differ in how aggressively they behave. A study of 24 strains isolated from women with lower urinary tract symptoms found that different strains showed varying tendencies to clump together in culture, a behavior called aggregation that may help the bacteria resist clearance from the urinary tract.¹⁰ More concerning for invasive disease, A. urinae isolates from human blood have been shown to form biofilms, and this biofilm formation is enhanced by human plasma.¹¹ Biofilms are communities of bacteria encased in a self-produced matrix that makes them much harder for both the immune system and antibiotics to reach. The fact that plasma promotes this behavior helps explain why A. urinae can cause such trouble once it enters the bloodstream.

Animal research has added another layer. In a mouse model of urinary tract infection, A. urinae triggered noticeable inflammation in the kidneys, with an influx of immune cells and elevated levels of certain inflammatory signaling molecules.¹² Different bacterial strains caused different degrees of kidney involvement, which aligns with the clinical observation that some A. urinae infections stay mild while others turn severe.

When Infection Spreads Beyond the Urinary Tract

The most feared complication of A. urinae infection is endocarditis, an infection of the heart valves. It is rare in absolute terms, but when it happens, the consequences are severe. A. urinae endocarditis carries a high risk of embolic events, where fragments of infected material break off from the heart valve and travel to the brain or other organs.¹³ Case reports have documented patients developing strokes from these emboli, with brain imaging revealing multiple areas of restricted blood flow across both hemispheres.¹⁴ In one case, a 49-year-old man presented with what appeared to be a simple UTI, then rapidly deteriorated with mitral valve endocarditis, a cerebral embolism causing stroke, and heart failure, dying two days after emergency surgery.¹³

The connection between the urinary tract and the heart may seem surprising, but the pathway is straightforward. Bacteria enter the bloodstream from the infected urinary tract, circulate, and seed the heart valves. A. urinae’s ability to activate platelets and form biofilms in the presence of plasma means it is well-equipped to colonize damaged heart tissue once it arrives.¹¹

Spinal disc infections, known as spondylodiscitis, are another documented complication. Fewer than ten cases of A. urinae spondylodiscitis had been reported as of recent reviews, but the number has been growing alongside improved identification methods.¹⁵ These infections, like endocarditis, appear to start with bacteria entering the blood from the urinary tract and then settling in the spine.¹⁶

Antibiotic Susceptibility and the Resistance Picture

The good news is that A. urinae remains susceptible to most of the antibiotics clinicians would reach for. In vitro testing has consistently shown low minimum inhibitory concentrations for penicillin, amoxicillin, ceftriaxone, cefotaxime, meropenem, vancomycin, linezolid, rifampin, and doxycycline.¹⁷ One study testing 120 Aerococcus isolates found 100% susceptibility to penicillin, cefotaxime, meropenem, vancomycin, linezolid, and rifampin.¹⁸ A larger study of 184 Aerococcus isolates confirmed 100% susceptibility to benzylpenicillin, ampicillin, meropenem, rifampicin, nitrofurantoin, and vancomycin.¹⁹

Fluoroquinolones are a different story. About 11% of Aerococcus isolates in that larger study were resistant to ciprofloxacin.¹⁹ Levofloxacin resistance appears even more variable. In a comparison study, about 23% of A. urinae isolates and a striking 78% of A. sanguinicola isolates had elevated levofloxacin resistance.⁷ Erythromycin and clindamycin susceptibility are also variable, with some strains resistant and others not.⁶ Fluoroquinolones are commonly prescribed for UTIs in general practice, which makes this resistance pattern clinically relevant: reaching for ciprofloxacin or levofloxacin as a reflex may not work against A. urinae, especially if a lab has misidentified it as an enterococcus.

The Trimethoprim-Sulfamethoxazole Testing Problem

One of the more peculiar issues with A. urinae is the confusion around trimethoprim-sulfamethoxazole (TMP-SMX), a common antibiotic combination used for UTIs. A. urinae has often been described in the literature as resistant to TMP-SMX. However, research has shown that this apparent resistance may be an artifact of the testing method. When tested in one type of broth (with lysed horse blood), clinical A. urinae isolates appeared fully susceptible. When the exact same isolates were tested in broth with lysed sheep blood, they appeared resistant.²⁰

A more recent evaluation reinforced the concern, finding that TMP-SMX testing by gradient diffusion strips produced a staggering 81% major error rate compared to the reference method, and ceftriaxone testing showed a 76% very major error rate. When agar dilution with lysed horse blood was used for TMP-SMX against 94 isolates, 100% tested susceptible.²¹ This matters because labs using the wrong testing medium could report false resistance, steering clinicians away from an effective oral antibiotic. Given that most A. urinae patients are elderly and would benefit from oral rather than intravenous therapy, accurate TMP-SMX results have real practical significance.

Treating Uncomplicated Versus Invasive Infections

For straightforward UTIs caused by A. urinae, standard beta-lactam antibiotics like amoxicillin tend to work well. The susceptibility data supports penicillins and cephalosporins as reliable first-line choices. Nitrofurantoin, a common UTI drug, also shows consistent activity.¹⁹

Invasive infections like endocarditis are a different challenge entirely. Laboratory studies have shown that combining penicillin or vancomycin with an aminoglycoside like gentamicin produces rapid killing that neither drug achieves alone.²² This synergistic effect has been confirmed in separate killing-kinetics experiments, including one showing that penicillin combined with either gentamicin or netilmicin was synergistic and appeared appropriate for treating A. urinae endocarditis.²³ For spondylodiscitis, the reported cases have been treated with various antibiotic combinations, but all have included a beta-lactam and begun with at least two weeks of intravenous antibiotics.¹⁵ There is no standardized treatment protocol for invasive A. urinae infections, so management is still guided by individual case experience and in vitro susceptibility data.

Aerococcus Urinae Versus Aerococcus Sanguinicola

A. urinae is the most commonly isolated Aerococcus species in clinical settings, but it is not the only one that causes human disease. In a nine-year retrospective study, A. urinae accounted for half of all Aerococcus isolates, while Aerococcus viridans made up about 30%.²⁴ A. sanguinicola, the other species of growing clinical interest, shares many features with A. urinae but has some important differences.

Both species affect older, often institutionalized patients with underlying urological conditions. However, A. sanguinicola tends to show much higher resistance to fluoroquinolones. In direct comparison, about 78% of A. sanguinicola isolates had elevated levofloxacin resistance, compared to about 23% of A. urinae.⁷ Both species had low resistance to ceftriaxone, penicillin, and vancomycin. Genomic analysis has revealed marked differences between the two species and even within A. urinae strains themselves, including variation in capsular structures that may influence how the bacteria evade the immune system.²

Life in Polymicrobial Biofilms

In catheterized patients, A. urinae rarely exists in isolation. Proteomic and genetic analysis of biofilms on urethral catheters has shown that A. urinae persists alongside gram-negative uropathogens in complex, multi-species communities.²⁵ These bacteria cohabitate across serially replaced catheters, meaning the community re-establishes itself even after catheter changes. The clinical implication is that simply swapping out a catheter is unlikely to eradicate A. urinae if it has established itself in the urinary tract.

This polymicrobial tendency extends to non-catheterized patients as well. A pediatric case series found that A. urinae was isolated as the sole organism in only two cases out of the entire series, with co-infection by other bacterial species being the norm.⁹ Whether A. urinae is the primary pathogen in these mixed cultures or a bystander remains unclear in many cases, and guidance on how to handle treatment decisions when it appears alongside other bacteria is still lacking. For clinicians, this ambiguity creates a real dilemma: should you treat A. urinae when it shows up in a culture alongside E. coli, or focus on the more familiar pathogen? The answer often depends on the clinical picture and whether symptoms persist after treating the more common organism.

What Genomic Diversity Means for the Future

Whole-genome sequencing of A. urinae strains has revealed that this is not a monolithic species. Among 40 clinical strains isolated over a span of more than three decades, researchers found marked differences in genome size, gene content, and putative capsular polysaccharide loci.² Capsular polysaccharides are sugar coatings on the bacterial surface that help shield the organism from immune attack, so variation in these structures could mean that some strains are better at evading your immune system than others.

The practical significance is that A. urinae infections may not all behave the same way. Some strains aggregate more readily, some form more robust biofilms, and some carry genetic features that could influence virulence. This genomic variability also complicates vaccine development and diagnostic standardization. As MALDI-TOF and sequencing technologies become more widespread in clinical labs, the next frontier is understanding whether strain-level differences predict which patients will develop a mild UTI versus those who will end up with endocarditis or a spinal infection. For now, that connection remains mostly speculative, but the genomic groundwork is being laid.